Extracted text (via pymupdf_layout)
16237 characters
DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice of Award Award# 5 NH28CE003540-04-00 Centers for Disease Control and Prevention FAIN# NH28CE003540 Federal Award Date: 08/25/2026 Recipient Information Federal Award Information 1. Recipient Name 11. Award Number MARICOPA, COUNTY OF 5 NH28CE003540-04-00 12. Unique Federal Award Identification Number (FAIN) 4041 N Central Ave Ste 1400 NH28CE003540 Community Health Services 13. Statutory Authority Phoenix, AZ 85012-3314 Section 311(c)(1) of the PHS Act (42 USC § 243(c)(1)) 602-506-1829 14. Federal Award Project Title 2. Congressional District of Recipient CDC-RFA-CE-23-0003 Overdose prevention and surveillance activities driven by data, community 09 partnerships, and a focus on health equity. 3. Payment System Identifier (ID) 1866000472B9 15. Assistance Listing Number 4. Employer Identification Number (EIN) 93.136 16. Assistance Listing Program Title 866000472 5. Data Universal Numbering System (DUNS) Injury Prevention and Control Research and State and Community Based Programs 602062515 6. Recipient’s Unique Entity Identifier (UEI) 17. Award Action Type LM85MG1513K5 Non-Competing Continuation 18. Is the Award R&D? 7. Project Director or Principal Investigator No Mr. Earl Harris earl.harris@maricopa.gov Summary Federal Award Financial Information 602-526-5822 19. Budget Period Start Date 09/01/2026 - End Date 08/31/2027 20. Total Amount of Federal Funds Obligated by this Action $3,255,202.00 8. Authorized Official 20a. Direct Cost Amount $2,901,157.00 Mr. John Lick 20b. Indirect Cost Amount $354,045.00 Grant Unit Manager 21. Authorized Carryover $0.00 john.lick@maricopa.gov 602-372-0675 22. Offset $0.00 23. Total Amount of Federal Funds Obligated this budget period $0.00 Fe deral Agency Information 24. Total Approved Cost Sharing or Matching, where applicable $0.00 CDC Office of Financial Resources 25. Total Federal and Non-Federal Approved this Budget Period $3,255,202.00 9. Awarding Agency Contact Information 26. Period of Performance Start Date 09/01/2023 - End Date 08/31/2028 Mr. Damond Barnes Grants Management Officer 27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Period of Performance $11,932,702.00 xhp5@cdc.gov 770-488-2611 28. Authorized Treatment of Program Income 10.Program Official Contact Information ADDITIONAL COSTS Mr. Yarkasah Paye 29. Grants Management Officer – Signature Pulic Health Advisor/Project Officer Mrs. Erica Stewart kvn7@cdc.gov Team Lead, Grants Management Officer 404.498.1839 30. Remarks Page 1 DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice of Award Centers for Disease Control and Prevention Award# 5 NH28CE003540-04-00 FAIN# NH28CE003540 Federal Award Date: 08/25/2026 Recipient Information 33. Approved Budget (Excludes Direct Assistance) Recipient Name I. Financial Assistance from the Federal Awarding Agency Only MARICOPA, COUNTY OF II. Total project costs including grant funds and all other financial participation 4041 N Central Ave Ste 1400 a. Salaries and Wages $585,376.00 Community Health Services b. Fringe Benefits $233,228.00 Phoenix, AZ 85012-3314 602-506-1829 c. Total Personnel Costs $818,604.00 d. Equipment $0.00 Congressional District of Recipient 09 e. Supplies $22,290.00 Payment Account Number and Type f. Travel $19,673.00 1866000472B9 Employer Identification Number (EIN) Data g. Construction $0.00 866000472 h. Other $58,898.00 Universal Numbering System (DUNS) i. Contractual $1,981,692.00 602062515 Recipient’s Unique Entity Identifier (UEI) j. TOTAL DIRECT COSTS $2,901,157.00 $2,901,157.00 LM85MG1513K5 k. INDIRECT COSTS $354,045.00 $354,045.00 31. Assistance Type l. TOTAL APPROVED BUDGET $3,255,202.00 $3,255,202.00 Cooperative Agreement m. Federal Share $3,255,202.00 $3,255,202.00 32. Type of Award Other n. Non-Federal Share $0.00 $0.00 34. Accounting Classification Codes FY-ACCOUNT NO. DOCUMENT NO. ADMINISTRATIVE CODE OBJECT CLASS ASSISTANCE LISTING AMT ACTION FINANCIAL ASSISTANCE APPROPRIATION 3-9390BX6 23NH28CE003540OPCE CE 410Q 93.136 $0.00 75-23-0952 4-9390BX6 23NH28CE003540OPCE CE 410Q 93.136 $0.00 75-24-0952 5-9390BX6 23NH28CE003540OPCE CE 410Q 93.136 $0.00 75-25-0952 6-9390BX6 23NH28CE003540OPCE CE 410Q 93.136 $3,255,202.00 75-26-0952 Page 2 DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice of Award Award# 5 NH28CE003540-04-00 Centers for Disease Control and Prevention FAIN# NH28CE003540 Federal Award Date: 08/25/2026 Direct Assistance BUDGET CATEGORIES PREVIOUS AMOUNT (A) AMOUNT THIS ACTION (B) TOTAL (A + B) Personnel $0.00 $0.00 $0.00 Fringe Benefits $0.00 $0.00 $0.00 Travel $0.00 $0.00 $0.00 Equipment $0.00 $0.00 $0.00 Supplies $0.00 $0.00 $0.00 Contractual $0.00 $0.00 $0.00 Construction $0.00 $0.00 $0.00 Other $0.00 $0.00 $0.00 Total 0.00 0.00 0.00 Page 3 AWARD ATTACHMENTS MARICOPA, COUNTY OF 5 NH28CE003540-04-00 1. Terms AWARD INFORMATION Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at https://www.cdc.gov/grants/federal-regulations- policies/index.html, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number CDC-RFA-CE-23-0003, entitled Overdose Data to Action in Localities, and application dated March 18, 2026, as may be amended, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NOA). Total Approved Funding is included in Summary Federal Award Financial Information on Page 1 of the NOA. All future year funding will be based on satisfactory programmatic progress and the availability of funds. The federal award amount is subject to adjustment based on total allowable costs incurred and/or the value of any third-party in-kind contribution when applicable. Note: Refer to the Payment Information section for Payment Management System (PMS) subaccount information. Approved Component/Project Funding: The NOFO provides for the funding of multiple components under this award. For this NOA, the approved funding level for each component is shown below: NOFO Component Amount Component A $ 3,255,202 Component B Component C Recipients are to review the Payment Management System (PMS) Subaccount section in this document to determine the appropriate subaccount document number for the referenced Component. Program specific authorizing legislation, budgetary appropriations, or similar authority may require the creation of more than one subaccount document number per award. Financial Assistance Mechanism: Cooperative Agreement Technical Review: Within 5 days of this Notice of Award’s (NOA) issue date, the Technical Review will be accessible to the recipient in GrantSolutions Grant Messages. Contact the assigned Program Officer indicated in the NOA with any questions regarding this document or any follow-up requirements and timelines set forth therein. Substantial Involvement by CDC: This is a cooperative agreement, and CDC will have substantial programmatic involvement after the award is made. Substantial involvement is in addition to all post-award monitoring, technical assistance, and performance reviews undertaken in the normal course of stewardship of federal funds. CDC program staff will assist, coordinate, or participate in carrying out effort under the award, and recipients agree to the responsibilities as detailed in the NOFO and included below. CDC will provide substantial involvement beyond regular performance and financial monitoring during the period of performance. Substantial involvement means that recipients can expect federal programmatic partnership in carrying out the effort under the award. CDC’s Division of Overdose Prevention (DOP), with support from the DOP Technical Assistance Center (TAC), will work in partnership with recipients to ensure the success of the cooperative agreement by: • Assisting in advancing program activities to achieve project outcomes • Providing technical assistance on data management plans • Collaborating with recipients to develop evaluation plans that align with CDC evaluation activities. • Providing technical assistance on the recipient’s Evaluation and Performance Measurement Plan • Providing technical assistance on recipient’s Targeted Evaluation Project • Providing technical assistance to define and operationalize performance measures • Facilitating the sharing of information among recipients • Participating in relevant meetings, committees, conference calls, and working groups related to - the cooperative agreement requirements • Coordinating communication and program linkages with other CDC programs and Federal agencies, such as the Centers for Medicare and Medicaid Services (CMS), Food and Drug Administration (FDA), the National Institutes of Health (NIH), Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Justice (DOJ), and the HHS Office of the National Coordinator for Health Information Technology (ONC) • Translating and disseminating lessons learned and best practices through publications, reports, technical packages, meetings, and other means to expand the evidence base; and • Identifying and awarding a partner organization to expand and strengthen recipients' capacity to implement surveillance and prevention activities through jurisdiction-level staffing support. Additionally, technical assistance around the funding announcement’s guiding principles (see Logic Model) will be available to ensure that all recipients are able to: • Collect data around community and demographic characteristics, including race and ethnicity, and conduct analyses that consider social determinants of health and use a health equity lens. • Use data to inform and tailor prevention programs, with emphasis on reaching groups disproportionately affected by the overdose epidemic; and • Ensure implementation of culturally relevant interventions and equitable delivery of prevention services. The TAC will leverage various modes of technical assistance, including group training, webinars, communities of practice, individualized one-on-one assistance, peer-to-peer interactions, and asynchronous learning to increase recipient capacity to implement evidence based interventions and successfully execute NOFO strategies. DOP staff and DOP TAC subject matter experts will work with the recipients to provide scientific subject matter expertise and resources by: • Providing cross-site and recipient-specific surveillance technical assistance, such as providing tools to identify nonfatal overdoses using standardized discharge diagnosis coding (i.e., ICD-10-CM) and unstandardized free text (e.g., chief complaint) • Providing cross-site and recipient-specific surveillance technical assistance, such as providing tools to identify fatal drug poisonings using ICD-10 cause of death codes and free text from the medical examiner and coroner reports • Providing guidance on SUDORS data abstraction, use of necessary data sharing platforms (e.g., NVDRS, NSSP ESSENCE), and CDC processes to collect required nonfatal data • Supporting the use of CDC’s nonfatal overdose case definitions by providing recipients computer programming code such as SAS, R, and ESSENCE to implement the cases definitions if resources are available • Providing ongoing data quality reviews and feedback on required nonfatal and fatal overdose data submissions • Providing guidance and technical assistance for Bio surveillance and Data Linkage projects to jurisdictions funded through the respective optional and competitive surveillance strategies • Coordinating health information technology and prescription drug monitoring program (PDMP) communication, program linkages, and technical assistance (TA) with other CDC programs, TA providers, and federal agencies, such as the Bureau of Justice Assistance (BJA), the HHS Office of the National Coordinator for Health Information Technology (ONC), and the PDMP Training and Technical Assistance Center (TTAC); and Providing guidance on using data to inform jurisdiction-level populations of focus, with a health equity lens, selecting evidence-based overdose prevention interventions, and implementing best practices across all four prevention strategies. Key Personnel: In addition to the Principal Investigator/Project Director identified in this Notice of Award, the application and work plan included individuals considered key personnel. In accordance 2 CFR 200.308 and 2 CFR 300.308, the recipient must request prior approval from CDC to change the following position: Authorized Organizational Representative (AOR) Budget Revision Requirement: The recipient must submit a revised budget for the reduced funding amount with a narrative justification by October 15, 2026. Failure to submit the required information in a timely manner may adversely affect the future funding of this project. If the information cannot be provided by the due date, you are required to contact the GMS/GMO identified in the CDC Staff Contacts section of this notice before the due date. Expanded Authority: The recipient is permitted the following expanded authority in the administration of the award. ☒ Carryover of unobligated balances from one budget period to a subsequent budget period. Unobligated funds may be used for purposes within the scope of the project as originally approved. Recipients will report use, or intended use, of carried over unobligated funds in Section 12 “Remarks” of the annual Federal Financial Report. If the GMO determines that some or all of the unobligated funds are not necessary to complete the project, the GMO may restrict the recipient’s authority to automatically carry over unobligated balances in the future, use the balance to reduce or offset CDC funding for a subsequent budget period, or use a combination of these actions. Program Income: Any program income generated under this grant or cooperative agreement will be used in accordance with the Cost sharing or matching alternative. Cost sharing alternative: Under this alternative, program income is used to finance some or the entire non-federal share of the project/program. Note: The disposition of program income must have written prior approval from the GMO. FUNDING RESTRICTIONS AND LIMITATIONS Indirect Costs: Indirect costs are not approved for this award, because indirect costs were not requested or an approved Indirect Cost Rate Agreement has not been established. To have indirect costs approved for this grant, submit an approved indirect cost rate agreement to the grants management specialist no later than January 31, 2027 REPORTING REQUIREMENTS Performance Progress and Monitoring: Performance information collection initiated under this grant/cooperative agreement has been approved by the Office of Management and Budget under OMB Number 0920-1132 “Performance Progress and Monitoring Report” Expiration Date February 28, 2029. The components of the PPMR are available for download at: https://www.cdc.gov/grants/already-have-grant/Reporting.html PROGRAM OR FUNDING GENERAL REQUIREMENTS Duplication of Effort: Recipients are responsible for reporting if this award will result in programmatic, budgetary, or commitment overlap with another application or award (i.e., grant, cooperative agreement, or contract) submitted to another funding source in the same fiscal year. Overlap, whether programmatic, budgetary, or commitment of an individual’s effort greater than 100 percent, is not permitted. Recipients are responsible for notifying the CDC Program Official and Grants Management Officer identified on this Notice of Award, if they become aware of programmatic, budgetary, or commitment overlap with another application or award. The overlap will be resolved by the CDC with the recipient and the PD/PI. PAYMENT INFORMATION Payment Management System Subaccount: Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, herein identified as the “P Account”. Funds must be used in support of approved activities in the NOFO and the approved application. The grant document numbers identified beginning on the bottom of Page 2 of the Notice of Award must be known in order to draw down funds.